Lung Cancer

Quantitative morphological features of tumor pathological images may help predict prognosis in patients with non-small cell lung cancer.

A study of the combination of radiation therapy and immune checkpoint inhibitors for the treatment of advanced lung cancer found a modest risk of side effects.

This video highlights some of the latest developments guiding precision medicine for lung cancer in clinical practice.

In this interview we discuss how quality-of-life information from patients with lung cancer can be used to help guide treatment and inform outcomes.

The use of reirradiation with intensity-modulated proton therapy yielded strong overall survival with limited toxicity in patients with thoracic tumors, potentially offering a new option in this patient population.

This video examines updated data from a phase II trial that compared a single dose of high-intensity SBRT with a standard three-dose schedule as treatment for patients with non-small-cell lung cancer.

This video examines the safety and efficacy of definitive stereotactic body radiation therapy in patients 80 and older with inoperable, early-stage lung cancer.

This video examines the results of a retrospective study that compared chemotherapy alone or with prophylactic cranial irradiation in extensive-stage SCLC patients with no brain metastases.

The use of a customized clinical pathways program that helps manage complexity and guide decisions resulted in a sharp decrease in costs per patient in an analysis of stage IV non–small-cell lung cancer.

ERBB2/HER2 mutations appear to be rare but targetable oncogenic drivers in non-small cell lung cancer, according to findings from a small retrospective cohort records analysis.

The LUX-Lung 7 trial found no significant differences between afatinib and gefitinib for patients with EGFR mutation–positive stage IIIb/IV NSCLC.

An IHC assay for ALK status in non-small cell lung cancer tumor tissue predicts crizotinib treatment outcomes and offers a rapid and potentially less expensive alternative to older FISH ALK status assays.

A better delineation of the relationships between lung cancer, COPD, and emphysema may lead to significant improvements in the effectiveness of lung cancer screening programs, and to reductions in the morbidity and mortality associated with these deadly diseases.

The addition of bevacizumab to a first-line regimen of cisplatin and etoposide improved progression-free survival in patients with extensive-disease small-cell lung cancer.

The oral ALK inhibitor ceritinib provided a significant improvement in progression-free survival over platinum-based chemotherapy in patients with previously untreated ALK-rearranged non-small-cell lung cancer.

A study just published in Cancer Cell is suggesting a new target for combating KRAS-mediated lung adenocarcinoma.

In my practice, I am constantly being asked how to properly treat scalp involvement in relation to these skin toxicities.

A delay in initiation of adjuvant chemotherapy following resection for non–small-cell lung cancer was not associated with any increase in mortality.

A database analysis shows significant shifts in treatment patterns for elderly patients diagnosed with advanced-stage non–small-cell lung cancer, along with a modest gain in survival since 2000.

Among active or former smokers undergoing lung cancer screening, longer peripheral leukocyte telomere length is associated with an increased risk of lung cancer.

Non-small cell lung cancer can acquire resistance to immune checkpoint blockade agents through evolutionary culling of tumor clones harboring the mutations for cell surface neoantigens that are recognized by patients’ immune T cells.

A 38-year-old woman presents with multiple pulmonary nodules. After further assessment a biopsy is performed. What is your diagnosis?

Pembrolizumab was associated with clinically meaningful improvements in health-related quality of life compared with platinum-based chemotherapy in NSCLC patients.

The PD-L1 inhibitor atezolizumab significantly improved overall survival compared with docetaxel across subgroups of patients with non–small-cell lung cancer.

Second-line treatment with osimertinib resulted in significantly better progression-free survival compared with chemotherapy alone in patients with EGFR-T790M positive NSCLC, according to the results of the AURA3 trial.

Patients treated with first-line ceritinib had a 45% reduction in the risk for progression of advanced ALK-positive NSCLC compared with chemotherapy.

In this slide show we highlight some of the top news on lung cancer in 2016, including an immunotherapy approval from the FDA, and studies on depression in lung cancer patients, serious side effects to watch for when using immunotherapies, and more.

An updated prognostic tool incorporating gene alteration data could help guide clinical management of patients with non–small-cell lung cancer.

Cabozantinib alone or in combination with erlotinib improved survival outcomes among patients with advanced EGFR wild-type non–small-cell lung cancer.

Researchers at UC San Francisco have recently discovered genetic mutations in a protective protein called Capicua (CIC). The scientists demonstrated that there is a disproportionate frequency of mutated CIC in human lung cancers that have metastasized.